Breaking News

REGENXBIO, Biogen in Gene Platform Pact

Biogen has exclusive license to NAV Technology Platform for development of two rare genetic vision disorders

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

REGENXBIO Inc. has entered an exclusive worldwide license agreement with Biogen for the development of gene therapy product candidates based on its NAV Technology Platform for the treatment of two rare genetic vision disorders. The NAV Technology Platform is an adeno-associated virus (AAV) gene delivery platform consisting of exclusive rights to more than 100 novel AAV vectors, including AAV7, AAV8, AAV9 and AAVrh10.   Biogen has an exclusive worldwide research license, with rights to sublicen...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters